National Policy: Access to Government Funded Immunoglobulin Products in Australia

Latest online version of the Criteria

An adaptation of the second edition of the Criteria is applicable in BloodSTAR from its launch in July 2016. The Criteria as they appear in BloodSTAR can be viewed here.

During the BloodSTAR transition period, the addition of ‘new’ Criteria ‘evidence items’ fields does not change the basis for approval of authorisation of Ig product. Authorisers will evaluate authorisation requests with the same approach that applies to authorisation based on the use of previous paper forms. 

The NBA has developed a national policy for access to Ig products funded under the national blood arrangements in Australia.  This document clarifies the roles and responsibilities for all stakeholders involved in the management of immunoglobulin, including:

  • roles, responsibilities, authority and accountability of those involved in requesting authorisation, authorising, supplying managing and using immunoglobulin products,
  • standardised national patient treatment access and review arrangements and processes 
  • coordinated and consistent in-hospital ordering and management to improve transparency of product inventory, ensure that product is provided to approved patients only and to reduce expiry related wastage.

The policy should be read in conjunction with the Criteria for the clinical use of immunoglobulin in Australia.

The policy was first released in 2014 and revised for the BloodSTAR release in July 2016. 

New South Wales use first edition (November 2014)


Northern Territory, South Australia, Queensland, Tasmania, Victoria, Australian Capital Territory and Western Australia use the second edition (July 2016)

Cover image of National Policy: Access to Government Funded Immunoglobulin Products in Australia  (pdf)

Contact us to iggovernance [at] (subject: Hard%20Copy%20Order%20of%20Ig%20National%20Policy) (order hard copies of the policy (July 2016))